The votes in favor of Merck's shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom are well-known vaccine critics.

Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who has ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some types of respiratory syncytial virus (RSV)-associated infections in infants.

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season. Skip to content Main Navigation ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck’s Clesrovimab (MK-1654), an investigational respiratory syncytial virus (RSV) preventative monoclonal antibody, significantly reduced incidence of RSV disease and hospitalization in ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season. Skip to content Main Navigation ...